BioSpace News Archive

Lantheus Holdings, Inc. announced it will be presenting at the Wells Fargo Securities 2018 Healthcare Conference on Wednesday, September 5 at the Westin Copley Place in Boston.

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Flex Pharma, Inc., Newell Brands, Inc., and PolarityTE, Inc.

Medicure Inc. reported its results from operations for the quarter ended June 30, 2018.

Inc. magazine today revealed that Akervall Technologies is No. 2318 on its 37th annual Inc. 5000, the most prestigious ranking of the nation’s fastest-growing private companies.

Telix Pharmaceuticals Limited and Nihon Medi-Physics Co., Ltd. have today announced that they have entered into a memorandum of understanding (MOU) for a commercial partnership in renal cancer imaging for the Japanese market.

Bernstein Liebhard LLP is investigating potential securities fraud claims on behalf of shareholders of Rockwell Medical, Inc.

IntriCon Corporation announced that it has priced an underwritten public offering of 1,500,000 shares of its common stock at a public offering price of $55.00 per share.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Kyowa Hakko Kirin Co. Ltd, and Kyowa Kirin International PLC today announced that the results of a pediatric Phase 2 clinical trial of Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia (XLH) in children aged 5 to 12 years were published online by the New England Journal of Medicine (NEJM).

The Patient Safety Authority has released a new Request for Proposals (RFP) to provide clinical analysis for its Pennsylvania Patient Safety Reporting System (PA-PSRS) data.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko Kirin Co. Ltd(Kyowa Hakko Kirin), and Kyowa Kirin International PLC today announced that the Phase 3 study of Crysvita® (burosumab) met its primary endpoint.